Get the Stockscreener App
3.28
5.75%
-0.20
After Hours:
3.42
0.14
+4.27%
Transcode Therapeutics Inc stock is traded at $3.28, with a volume of 40,470.
It is down -5.75% in the last 24 hours and down -61.77% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$3.48
Open:
$3.5
24h Volume:
40,470
Relative Volume:
0.67
Market Cap:
$3.47M
Revenue:
-
Net Income/Loss:
$-40.36M
P/E Ratio:
-0.0674
EPS:
-48.648
Net Cash Flow:
$-21.40M
1W Performance:
-17.17%
1M Performance:
-61.77%
6M Performance:
-64.39%
1Y Performance:
-70.32%
1-Day Range:
$3.21
$3.70
1-Week Range:
$3.21
$4.26
52-Week Range:
$3.21
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
3.28 | 3.57M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Corsicana Daily Sun
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - Stock Titan
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnProfit Announcement - dars.gov.et
RNAZ|Transcode Therapeutics Inc|Price:5.800|Chg%:-0.130 - TradingKey
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions - Stock Titan
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNAZ|Transcode Therapeutics Inc|Price:5.930|Chg%:-1.170 - TradingKey
Transcode Therapeutics Inc (RNAZ) Balance Sheet - TradingKey
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
RNAZ|Transcode Therapeutics Inc|Price:3.995|Chg%:+0.035 - TradingKey
Transcode Therapeutics Inc (RNAZ) Cash Flow - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
ON: ON Semiconductor Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
TransCode Therapeutics (RNAZ) Proxy Filing Summary - Quartr
TransCode Therapeutics, Inc. (RNAZ) 8-K: Key Nasdaq Approvals and Stockholder Vote Results July 2026 - Minichart
TransCode Therapeutics Inc. (RNAZ) Q4 2024 Earnings: Deep Losses on No Revenue as Cash Burn Persists - dars.gov.et
TransCode Therapeutics Shareholders Approve Key Capital Measures - TipRanks
TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
TransCode Therapeutics Updates Preferred Stock Ownership Limits - The Globe and Mail
Form 13D/A TransCode Therapeutics For: 17 July By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) investor to convert preferred stock toward 9.99% stake - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) raises Series C ownership cap to 9.99% - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
Understanding Momentum Shifts in (RNAZ) - Stock Traders Daily
Price to earnings forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Enterprise value to EBIT forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to book forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Enterprise value to EBITDA forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to sales forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
TransCode Therapeutics (RNAZ) Surges Over 9% as Shares Test Key Resistance LevelsDemand Zone - dars.gov.et
RNAZ | TransCode Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (RNAZ) Movement - Stock Traders Daily
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps - TipRanks
Nasdaq review delays TransCode (NASDAQ: RNAZ) vote on preferred conversion - Stock Titan
TransCode Therapeutics adjourns 2026 annual meeting to July 20 pending Nasdaq initial listing review - TradingView
TransCode Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAZ) - TradingView
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):